| |
|
|
|
Xtalks, Online
2025-05-29
Steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), is one of the most common forms of chronic liver disease, with an estimated prevalence of about 30 percent across many countries.
The I148M genotype variant of the PNPLA3 gene is associated with MASH / MASLD disease severity and fibrosis progression even in the absence of classical metabolic dysfunction (including obesity). Conversely, single nucleotide polymorphisms (SNPs) within or close to the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene is associated with reduced risk and severity of MASH / MASLD disease and as such both genes are of significant research interest to the field.
The expert speakers will focus on how using PNPLA3 and HSD17B13 clinical trial assays for clinical trial use and a PNPLA3 genotyping kit for research use provide researchers with better insights into MASH/MASLD biology. This webinar explores some of the realities of a precision medicine approach to SLD from a diagnostic providers’ perspective.
Register for this webinar today to discuss the impact of genetic markers on the severity and treatment of MASH/MASLD and how clinical trial assays and genotyping kits can enhance research and clinical insight.
Keywords: Clinical Trials, Precision Medicine, Chronic Disease, CRO, Liver Disease, Biomarkers, NASH, Diagnostics, Therapeutic Areas, Translational Medicine, Molecular Biomarkers, MASH, Companion Diagnostics (CDx), MASLD
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Steven Walker, Director of Product Management, Almac Diagnostic Services
Dr. Cheryl McFarlane, Associate Director, Assay Development & Validation, Almac Diagnostic Services
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-05-29
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|